ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2177

Familial Clustering of Systemic Sclerosis, Autoimmunity, and Cancer History

Mariana Bombini1, Nailú Sinicato1, Jacqueline Paredes2, Theresa Wampler Muskardin2, Tiago Nardi Amaral1, Ana Paula Del Rio1, Joao Marques Neto3, Timothy Niewold2 and Simone Appenzeller4, 1State University of Campinas, Campinas, São Paulo, Brazil, 2Hospital for Special Surgery, New York, NY, 3State University of Campinas, São Paulo, Brazil, 4Unicamp, Campinas, São Paulo, Brazil

Meeting: ACR Convergence 2022

Keywords: Epidemiology, genetics, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic sclerosis (SSc) is a complex disease characterized by chronic inflammation, fibrosis, and vasculopathy. Genetic factors contribute to pathogenesis, but because it is a rare disease familial aggregation is uncommon and hard to detect. Cancer risk is increased in SSc patients, but it is not known whether this represents a shared genetic risk factor or a downstream effect of the disease. In this study we analyze 100 large families from Brazil for recurrence rates of SSc across three generations, along with risk of other autoimmune diseases and familial risk of cancer.

Methods: A total of 100 SSc consecutive patients were enrolled at the Rheumatology outpatient clinic at the State University of Campinas – UNICAMP, located in Southeastern Brazil. Patients who met the ACR/EULAR 2013 Criteria for SSc were included in this study. Personal interviews were conducted with each SSc patient to obtain data on a familial history of SSc, other autoimmune and rheumatic conditions, and neoplasia in the extended family. Large familial pedigrees inclusive of 3 degrees of relation to the SSc patient were drawn using the information obtained, and diagnoses of the relatives were analyzed within this framework.

Results: We observed a first-degree relative recurrence rate of 44.9 for SSc, which fell to 20.5 in second degree relatives, and 3.5 in third degree relatives. This recurrence rate pattern fits a polygenic inheritance model. We also observed a significantly increased rate of rheumatoid arthritis and SLE in first degree relatives (for RA, OR=4.5, p=3×10-5; for SLE OR=7.05, p=0.04). Risk of these other autoimmune diseases was not significantly increased in second and third degree relatives. First degree relatives were reported to have breast cancer and stomach or esophagus cancer more frequently than second or third degree relatives (breast cancer OR=3.5, p=0.0056, stomach or esophagus OR=3.0, p=0.0077). A similar non-significant trend was observed in lung cancer in first degree relatives (OR=2.4, p=0.14 as compared to second and third degree relatives). Leukemia was reported more commonly in first and second degree relatives as compared to third degree relatives (OR=8.1, p=0.019).

Conclusion: We observed significant familial clustering of SSc, which fits a polygenic inheritance model. Rates of RA and SLE were significantly increased in first degree relatives, supporting the idea of shared genetic factors. Some cancers were reported more commonly in relatives that were more closely related to the SSc patient, as compared to more distant relatives. While these data are subject to the limitations inherent in family history studies, it could suggest a shared genetic cancer predisposition in SSc families. Studies in additional populations are needed to confirm this finding.


Disclosures: M. Bombini, None; N. Sinicato, None; J. Paredes, None; T. Wampler Muskardin, None; T. Nardi Amaral, None; A. Del Rio, None; J. Marques Neto, None; T. Niewold, None; S. Appenzeller, None.

To cite this abstract in AMA style:

Bombini M, Sinicato N, Paredes J, Wampler Muskardin T, Nardi Amaral T, Del Rio A, Marques Neto J, Niewold T, Appenzeller S. Familial Clustering of Systemic Sclerosis, Autoimmunity, and Cancer History [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/familial-clustering-of-systemic-sclerosis-autoimmunity-and-cancer-history/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/familial-clustering-of-systemic-sclerosis-autoimmunity-and-cancer-history/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology